Imatinib has been approved by the Food and Drug Administration (FDA) for the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST) expressing KIT. Here, KIT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.